Physician profile
Ali A Khan
NPI 1598870503
$7,287.05
in general payments reported to CMS, 2019-2025
38 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $560 · 2021: $1,180 · 2022: $1,205 · 2023: $754 · 2024: $714 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,158.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $699.34 | 2025 | |
| Janssen Pharmaceuticals, INC | $676.24 | 2019-2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $646.80 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $600.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $541.07 | 2019-2025 | Korlym |
| Amgen INC. | $507.01 | 2019-2025 | Repatha |
| Astellas Pharma US INC | $421.87 | 2019-2023 | Veozah |
| Mylan Specialty L.P. | $308.64 | 2019-2023 | Yupelri |
| Pfizer INC. | $203.31 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.36 | 2021-2025 | |
| Horizon Therapeutics Plc | $179.51 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $179.14 | 2019-2023 | Seglentis, Livalo |
| Exact Sciences Corporation | $169.12 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $161.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $157.10 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.19 | 2023-2025 | Lifevest |
| Esperion Therapeutics, INC. | $137.33 | 2020-2021 | |
| Lilly USA, LLC | $129.92 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $124.19 | 2023-2025 | Auvelity |
| Abbvie INC. | $119.50 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $117.01 | 2024 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $115.09 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $109.56 | 2019-2023 | Ingrezza |
| Medtronic, INC. | $108.98 | 2025 | Corevalve Evolut R |
| Biogen, INC. | $75.19 | 2020-2021 | |
| Lundbeck LLC | $72.35 | 2025 | Rexulti |
| Indivior INC. | $60.56 | 2019-2020 | |
| Amarin Pharma, INC. | $56.09 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $40.17 | 2021 | |
| Glaxosmithkline, LLC. | $37.86 | 2023-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.30 | 2019-2020 | |
| Capsovision, INC. | $25.95 | 2024 | Capsocam Plus |
| Angiodynamics, INC. | $25.87 | 2023 | Alphavac |
| Pulmonx Corporation | $20.77 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Scpharmaceuticals INC. | $19.85 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.54 | 2022 | |
| Sumitomo Pharma America, INC. | $17.50 | 2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.77 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.